Bromodomain
Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2)
pipeline Target constitutes close to 8 molecules. The latest report Bromodomain
Containing Protein 2 - Pipeline Review, H1 2018, outlays comprehensive
information on the Bromodomain Containing Protein 2 (Really Interesting New
Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics, complete with
analysis by indications, stage of development, mechanism of action (MoA), route
of administration (RoA) and molecule type.
Bromodomain
Containing Protein 2 (Really
Interesting New Gene 3 Protein or O27.1.1 or BRD2) - Bromodomain-containing
protein 2 is a protein that is encoded by the BRD2 gene. It plays a role in
spermatogenesis. It plays a role in the regulation of transcription, probably
by chromatin remodeling and also plays a role in nucleosome assembly. It
regulates transcription of the CCND1 gene.
The
molecules developed by companies in Phase II, Phase I and Preclinical stages
are 3, 2 and 3 respectively. Report covers products from therapy areas
Oncology, Dermatology, Immunology and Respiratory which include indications
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer,
Diffuse Large B-Cell Lymphoma, Multiple Myeloma (Kahler Disease), Atopic
Dermatitis, Myelodysplastic Syndrome, NUT Midline Carcinoma (NMC or Nuclear
Protein in Testis Midline Carcinoma), Psoriasis, Refractory Acute Myeloid
Leukemia, Relapsed Acute Myeloid Leukemia, Acute Lymphocytic Leukemia (ALL,
Acute Lymphoblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Colon Cancer,
Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Idiopathic
Pulmonary Fibrosis, Inflammation, Lung Cancer, Malignant Pleural Mesothelioma,
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent)
Prostate Cancer, Myelofibrosis, Non-Small Cell Lung Cancer, Ovarian Cancer,
Pancreatic Ductal Adenocarcinoma, Prostate Cancer, Refractory Multiple Myeloma,
Relapsed Multiple Myeloma, Rheumatoid Arthritis, Solid Tumor, Systemic Lupus
Erythematosus and Systemic Sclerosis (Scleroderma).
Furthermore,
this report also reviews key players involved in Bromodomain Containing Protein
2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted
therapeutics development with respective active and dormant or discontinued
projects. Driven by data and information sourced from proprietary databases,
company/university websites, clinical trial registries, conferences, SEC
filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources.
The
report provides a snapshot of the global therapeutic landscape for Bromodomain
Containing Protein 2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2)
The
report reviews Bromodomain Containing Protein 2 (Really Interesting New Gene 3
Protein or O27.1.1 or BRD2) targeted therapeutics under development by
companies and universities/research institutes based on information derived
from company and industry-specific sources
The
report covers pipeline products based on various stages of development ranging
from pre-registration till discovery and undisclosed stages
The
report features descriptive drug profiles for the pipeline products which
includes, product description, descriptive MoA, R&D brief, licensing and
collaboration details & other developmental activities
The
report reviews key players involved in Bromodomain Containing Protein 2 (Really
Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted therapeutics and
enlists all their major and minor projects
The
report assesses Bromodomain Containing Protein 2 (Really Interesting New Gene 3
Protein or O27.1.1 or BRD2) targeted therapeutics based on mechanism of action
(MoA), route of administration (RoA) and molecule type
The
report summarizes all the dormant and discontinued pipeline projects
The
report reviews latest news and deals related to Bromodomain Containing Protein
2 (Really Interesting New Gene 3 Protein or O27.1.1 or BRD2) targeted
therapeutics
To know more click on the link below:
Related Reports:
Contact Us:
Ken
Research
Ankur
Gupta, Head Marketing & Communications
0124-4230204